SCHEMBL4037434

SCHEMBL4037434

O=C(NC1CCCCC1)C(C1CCCCO1)C1(c2ccc(Cl)cc2)Nc2cc(F)c(Cl)cc2N1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.42
KCNH2 Q12809 3/20 0.42
NR1H4 Q96RI1 3/20 0.42
RAB9A P51151 4/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP2C9 P11712 3/20 0.37
CYP2D6 P10635 2/20 0.37
EPHX1 P07099 2/20 0.35
SLC6A3 Q01959 4/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD11B1 P28845 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037949 0.90 RAB9A (0.36) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4041093 0.90 RAB9A (0.36) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4038000 0.90 RAB9A (0.36) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4038655 0.90 KCNH2 (0.48) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4034374 0.90 KCNH2 (0.48) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4036578 0.90 KCNH2 (0.48) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4036376 0.90 KCNH2 (0.48) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4039537 0.90 KCNH2 (0.48) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4038118 0.88 NR1H4 (0.44) CYP3A4KCNH2NR1H4RAB9ANPC1
SCHEMBL4039331 0.88 NR1H4 (0.44) CYP3A4KCNH2NR1H4RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed